Positive newborn screen: a case of a novel variant in DCLRE1C in a patient with SCID

Publication: LymphoSign Journal
10 March 2020

Abstract

Background: Artemis enzyme, encoded by the DCLRE1C gene, is essential to V(D)J recombination in both T and B lymphocytes. Artemis functions as an important component of the nonhomologous end-joining DNA double-strand break repair pathway. Artemis deficiency leads to a T-B-NK+ severe combined immune deficiency (SCID) associated with radiosensitivity.
Clinical presentation: We present a case of a positive newborn screen for SCID in a patient who was subsequently shown to have a T-B-NK+ phenotype. Further immune evaluation showed profound T and B lymphopenia, near-absent response to mitogen stimulation, and absent immunoglobulins A and M. Genetic investigation demonstrated a novel and putative pathogenic variant in the DCLRE1C gene.
Conclusion: This case identifies a novel variant in the DCLRE1C gene in a patient with SCID identified by newborn screening.
Statement of novelty: This case report identifies a novel variant in the DCLRE1C gene in a patient with T-B-NK+ SCID.

Formats available

You can view the full content in the following formats:

REFERENCES

Felgentreff K., Lee Y.N., Frugoni F., Du L., van der Burg M., Giliani S., Tezcan I., Reisli I., Mejstrikova E., de Villartay J.P., Sleckman B.P., Manis J., and Notarangelo L.D. 2015. Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency. J. Allergy Clin. Immunol. 136(1):140–150.e7.
Lee P.P., Woodbine L., Gilmour K.C., Bibi S., Cale C.M., Amrolia P.J., Veys P.A., Davies E.G., Jeggo P.A., and Jones A. 2013. The many faces of Artemis-deficient combined immunodeficiency—Two patients with DCLRE1C mutations and a systematic literature review of genotype–phenotype correlation. Clin. Immunol. 149(3):464–474.
Mancebo E., Recio M.J., Martínez-Busto E., González-Granado L.I., Rojo P., Fernández-Díaz E., Ruiz-Contreras J., Paz-Artal E., and Allende L.M. 2011. Possible role of Artemis c.512C>G polymorphic variant in Omenn syndrome. DNA Repair. 10(1):3–4.
Moshous D., Callebaut I., Chasseval R., Corneo B., Cavazzana-Calvo M., Le Deist F., Tezcan I., Sanal O., Bertrand Y., Philippe N., Fischer A., and de Villartay J.-P. 2001. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 105(4):177–186.
Pannicke U., Hönig M., Schulze I., Rohr J., Heinz G.A., Braun S., Janz I., Rump E.M., Seidel M.G., Matthes-Martin S., Soerensen J., Greil J., Stachel D.K., Belohradsky B.H., Albert M.H., Schulz A., Ehl S., Friedrich W., and Schwarz K. 2010. The most frequent DCLRE1C (ARTEMIS) mutations are based on homologous recombination events. Hum. Mutat. 31(2):197–207.
Sundin M., Marits P., Ramme K., Kolios A.G., and Nilsson J. 2019. Severe combined immunodeficiency (SCID) presenting in childhood, with agammaglobulinemia, associated with novel compound heterozygous mutations in DCLRE1C. Clin. Immunol. 200:16–18.
Woodbine L., Grigoriadou S., Goodarzi A.A., Riballo E., Tape C., Oliver A.W., van Zelm M.C., Buckland M.S., Davies E.G., Pearl L.H., and Jeggo P.A. 2010. An Artemis polymorphic variant reduces Artemis activity and confers cellular radiosensitivity. DNA Repair. 9(9):1003–1010.

Information & Authors

Information

Published In

cover image LymphoSign Journal
LymphoSign Journal
Volume 7Number 1March 2020
Pages: 46 - 48

History

Received: 8 January 2020
Accepted: 28 January 2020
Accepted manuscript online: 10 March 2020

Authors

Affiliations

Noreen Choe
Division of Rheumatology, Clinical Immunology, and Allergy, Department of Pediatrics, McMaster Children’s Hospital, Hamilton, ON
Lauren Brick
Division of Metabolics and Genetics, Department of Pediatrics, McMaster Children’s Hospital, Hamilton, ON
Mariya Kozenko
Division of Metabolics and Genetics, Department of Pediatrics, McMaster Children’s Hospital, Hamilton, ON
Pranesh Chakraborty
Division of Metabolics and Newborn Screening, Department of Pediatrics, University of Ottawa, and Newborn Screening Ontario, Ottawa, ON
Kristin D. Kernohan
Division of Metabolics and Newborn Screening, Department of Pediatrics, University of Ottawa, and Newborn Screening Ontario, Ottawa, ON
Dennis Bulman
Division of Metabolics and Newborn Screening, Department of Pediatrics, University of Ottawa, and Newborn Screening Ontario, Ottawa, ON
Division of Rheumatology, Clinical Immunology, and Allergy, Department of Pediatrics, McMaster Children’s Hospital, Hamilton, ON

Competing Interests

Dr. Brager has received honoraria from Takeda and Sanofi.

Funding Information

This case report was not funded.

Metrics & Citations

Metrics

Other Metrics

Citations

Cite As

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

There are no citations for this item

View Options

View options

PDF

View PDF

Full Text

View Full Text

Get Access

Login options

Check if you access through your login credentials or your institution to get full access on this article.

Subscribe

Click on the button below to subscribe to LymphoSign Journal

Purchase options

Purchase this article to get full access to it.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Media

Media

Other

Tables

Share Options

Share

Share the article link

Share on social media